A clinical trial comparing Armour Thyroid (NDT) and Levothyroxine (LT4) is now recruiting patients in the United States. The sponsor of the study is Allergan, the makers of Armour Thyroid in the United States. They hope to recruit 220 patients… Read More ›
There’s no surprise that patients and doctors would disagree about the incidence rate of hypothyroid symptoms in a given patient. “We have an average of 7.2 symptoms per patient” says the cohort of 262 patients. “No, you have an average… Read More ›
In this Part 3, I continue my rebuttal of a research article that blames thyroid patients for causing harm to themselves by making requests of doctors for tests and therapies.
In this post, I explain the good signs that thyroid patients’ self-advocacy is sometimes effective and is making a difference.
We all know a “thyroidectomy” is the surgical removal of a thyroid gland. Nobody removes a vital gland without a patient’s informed consent. If your medical system and doctor are ethical, you as a patient have the opportunity to weigh… Read More ›
What does NEW thyroid science have to say on the topic of thyroid pharmaceutical equivalency? How many micrograms of L-T3 Liothyronine (i.e. Cytomel) are equivalent to L-T4 Levothyroxine (i.e. Synthroid)? Thyroid hormone pharmaceutical monographs currently provide very rigid and low-ratio… Read More ›
In thyroid therapy, how many micrograms of Cytomel (T3) are equivalent to how many micrograms of Synthroid (T4)? Equivalency statements in the product monographs for Pfizer Canada’s Cytomel and for ERFA Canada’s “Thyroid” (NDT brand) claim that a 25 mcg… Read More ›
Here, I’ll use my own personal example to discuss a few dimensions of T3 monotherapy, which I envision as a “wheelchair.” I’m drawing on the fictional analogy I developed in an earlier post, where I imagined thyroid disease like crippling… Read More ›